Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dean G Tang

Showing results (111-120 of 133) with videos related to

Pageof 14
Sort By:
Development (Cambridge, England)|February 6, 2019
USP22 controls multiple signaling pathways that are essential for vasculature formation in the mouse placentaEvangelia Koutelou, Li Wang, Andria C Schibler, et al.
The Journal of Biological Chemistry|July 30, 2008
Critical and distinct roles of p16 and telomerase in regulating the proliferative life span of normal human prostate epithelial progenitor cellsBobby Bhatia, Ming Jiang, Mahipal Suraneni, et al.
Medrxiv : the Preprint Server for Health Sciences|February 6, 2026
The temporal dynamics of the immune response to neoadjuvant androgen deprivation therapy suggests a window-of-opportunity for checkpoint inhibitor therapy in prostate cancerAnmbreen Jamroze, Renyuan Zhang, Kriti Ahuja, et al.
Oncotarget|August 7, 2015
Systematic dissection of phenotypic, functional, and tumorigenic heterogeneity of human prostate cancer cellsXin Liu, Xin Chen, Kiera Rycaj, et al.
Signal Transduction and Targeted Therapy|May 1, 2026
Single-cell imaging analysis, therapeutic modeling and a Phase Ib trial validate BCL-2 as a target across heterogeneous castration-resistant prostate cancerAnmbreen Jamroze, Xiaozhuo Liu, Surui Hou, et al.
Pathology Oncology Research : POR|January 1, 1996
Prostate Cancer - Old Problems and New Approaches. (Part II. Diagnostic and Prognostic Markers, Pathology and Biological Aspects)Kenneth V Honn, Amer Aref, Yong Q Chen, et al.
Pathology Oncology Research : POR|January 1, 1996
Prostate Cancer Old Problems and New Approaches. Part III. Prevention and TreatmentKenneth V Honn, Amer Aref, Yong Q Chen, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 23, 2021
A glutaminase isoform switch drives therapeutic resistance and disease progression of prostate cancerLingfan Xu, Yu Yin, Yanjing Li, et al.
Biorxiv : the Preprint Server for Biology|June 4, 2026
A targetable opioid/cancer associated fibroblast axis drives extracellular matrix remodeling and tumor aggressiveness in pancreatic cancerKathryn E Maraszek, Arwen A Tisdale, Hunter D Reavis, et al.
Biorxiv : the Preprint Server for Biology|March 22, 2023
Integrated single-cell analysis defines the epigenetic basis of castration-resistant prostate luminal cellsJason S Kirk, Jie Wang, Amanda Tracz, et al.
Pageof 14

Showing results (111-120 of 133) with videos related to

Sort By:
Pageof 14
Development (Cambridge, England)|February 6, 2019
USP22 controls multiple signaling pathways that are essential for vasculature formation in the mouse placentaEvangelia Koutelou, Li Wang, Andria C Schibler, et al.
The Journal of Biological Chemistry|July 30, 2008
Critical and distinct roles of p16 and telomerase in regulating the proliferative life span of normal human prostate epithelial progenitor cellsBobby Bhatia, Ming Jiang, Mahipal Suraneni, et al.
Medrxiv : the Preprint Server for Health Sciences|February 6, 2026
The temporal dynamics of the immune response to neoadjuvant androgen deprivation therapy suggests a window-of-opportunity for checkpoint inhibitor therapy in prostate cancerAnmbreen Jamroze, Renyuan Zhang, Kriti Ahuja, et al.
Oncotarget|August 7, 2015
Systematic dissection of phenotypic, functional, and tumorigenic heterogeneity of human prostate cancer cellsXin Liu, Xin Chen, Kiera Rycaj, et al.
Signal Transduction and Targeted Therapy|May 1, 2026
Single-cell imaging analysis, therapeutic modeling and a Phase Ib trial validate BCL-2 as a target across heterogeneous castration-resistant prostate cancerAnmbreen Jamroze, Xiaozhuo Liu, Surui Hou, et al.
Pathology Oncology Research : POR|January 1, 1996
Prostate Cancer - Old Problems and New Approaches. (Part II. Diagnostic and Prognostic Markers, Pathology and Biological Aspects)Kenneth V Honn, Amer Aref, Yong Q Chen, et al.
Pathology Oncology Research : POR|January 1, 1996
Prostate Cancer Old Problems and New Approaches. Part III. Prevention and TreatmentKenneth V Honn, Amer Aref, Yong Q Chen, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 23, 2021
A glutaminase isoform switch drives therapeutic resistance and disease progression of prostate cancerLingfan Xu, Yu Yin, Yanjing Li, et al.
Biorxiv : the Preprint Server for Biology|June 4, 2026
A targetable opioid/cancer associated fibroblast axis drives extracellular matrix remodeling and tumor aggressiveness in pancreatic cancerKathryn E Maraszek, Arwen A Tisdale, Hunter D Reavis, et al.
Biorxiv : the Preprint Server for Biology|March 22, 2023
Integrated single-cell analysis defines the epigenetic basis of castration-resistant prostate luminal cellsJason S Kirk, Jie Wang, Amanda Tracz, et al.
Pageof 14